Sample 63

Evaluation Instructions

Important: Models were tasked with extracting evidence from documents. Some outputs may be low quality and should be scored accordingly.

Your task: Compare the model-generated prediction (right panel) against the ground truth criteria (left panel).

Evaluation scale (0-4):

Consider both content accuracy and completeness. Some predictions may be technically "correct" but incomplete or out of order.

Ground Truth

INCLUSION CRITERIA

  1. Diagnosed with RRMS per revised Mc
  2. Donald criteria (2017) with an EDSS score ≤ 6.5 at screening
  3. Neurologically stable with no evidence of relapse within the 28 days before signing the informed consent form (ICF)
  4. Either not currently receiving disease modifying MS therapy, or currently using fumarate drugs (dimethyl fumarate or diroximel fumarate)
  5. Patients must use a highly effective method of birth control or are sterile or postmenopausal as confirmed by study Investigator
  6. Patient has signed and understands the ICF

EXCLUSION CRITERIA

  1. Diagnosis of primary progressive MS or secondary progressive MSUncontrolled or significant medical conditions (including active infection or chronic hepatitis) which, in the opinion of the Investigator, preclude participation
  2. Patients treated with glatiramer acetate, parenteral steroids or adrenocorticotropic hormone, β-interferon, plasma exchange within the 3 months prior to first dose
  3. Patients treated with sphingosine-1-phospate receptor modulators such as fingolimod, ozanimod, or siponimod within 6 months prior to first dose
  4. Patients treated with cytotoxic agents (including, but not limited to, cladribine, mitoxantrone, cyclophosphamide, azathioprine, and methotrexate), laquinimod, teriflunomide, or IV gamma globulin within 12 months prior to first dose
  5. Patients treated with monoclonal antibody therapy (including natalizumab, daclizumab, rituximab, ofatumumab, and ocrelizumab) within 24 months prior to first dose
  6. Patients previously treated with alemtuzumab, total lymphoid irradiation, mesenchymal stem cell or hematopoietic stem cell transplantation, or tolerance-inducing therapies for MSContraindication to or inability to undergo gadolinium-enhanced magnetic resonance imaging (MRI) scan
  7. Use of any investigational drug or experimental procedure within previous 6 months that would interfere with the assessment of ANK-700
  8. Patients who are pregnant or breastfeeding
  9. Patients receiving any vaccination within 28 days prior to first dose
  10. Patient does not agree to limit alcohol intake to 2 drink equivalents or less per day during the study

Prediction

Revised Eligibility Criteria for Version 8 Clinical Trial

Original Eligibility Criteria (Version 7):

INCLUSION CRITERIA

  1. Diagnosed with RRMS per revised McDonald criteria (2017)
  2. With an EDSS score ≤ 6.5 at screening
  3. Neurologically stable with no evidence of relapse within the 28 days before signing the informed consent form (ICF)

EXCLUSION CRITERIA

  1. Diagnosis of primary progressive MS or secondary progressive MS
  2. Uncontrolled or significant medical conditions (including active infection or chronic hepatitis)
  3. Which, in the opinion of the Investigator, preclude participation
  4. Treatment with glatiramer acetate, parenteral steroids, or adrenocorticotropic hormone, β-interferon, plasma exchange within the 3 months prior to first dose
  5. Treatment with sphingosine-1-phosphate receptor modulators such as fingolimod, ozanimod, or siponimod within 6 months prior to first dose
  6. Treatment with cytotoxic agents (including, but not limited to, cladribine, mitoxantrone, cyclophosphamide, azathioprine, and methotrexate), laquinimod, teriflunomide, or IV gamma globulin within 12 months prior to first dose
  7. Treatment with monoclonal antibody therapy (including natalizumab, daclizumab, rituximab, ofatumumab, and ocrelizumab) within 24 months prior to first dose
  8. Previous treatment with alemtuzumab, total lymphoid irradiation, mesenchymal stem cells or hematopoietic stem cells transplantation, or tolerance-inducing therapies for MS
  9. Updated Eligibility Criteria (Version 8):

INCLUSION CRITERIA

  1. Male or female adults aged 18 to 60 years inclusive at screening
  2. Diagnosed with RRMS per revised McDonald criteria (2017) with an EDSS score ≤ 6.5 at screening
  3. Neurologically stable with no evidence of relapse within the 28 days prior to signing the informed consent form (ICF)
  4. Either not currently receiving disease modifying MS therapy, or currently using fumarate drugs (i.e., dimethyl fumarate, diroximel fumarate)
  5. Patients must use a highly effective method of birth control or are sterile or postmenopausal as confirmed by study investigator for the first 3 months (through D90) of the study
  6. Patient has signed and understood the ICF
  7. Patient has signed and understood the ICF
  8. Patient has signed and understood the ICF
  9. Patient has signed and understood the ICF
  10. Patient has signed and understood the ICF
  11. Patient has signed and understood the ICF
  12. Patient has signed and understood the ICF
  13. Patient has signed and understood the ICF
  14. Patient has signed and understood the ICF
  15. Patient has signed and understood the ICF
  16. Patient has signed and understood the ICF
  17. Patient has signed and understood the ICF
  18. Patient has signed and understood the ICF
  19. Patient has signed and understood the ICF
  20. Patient has signed and understood the ICF
  21. Patient has signed and understood the ICF
  22. Patient has signed and understood the ICF
  23. Patient has signed and understood the ICF
  24. Patient has signed and understood the ICF
  25. Patient has signed and understood the ICF
  26. Patient has signed and understood the ICF
  27. Patient has signed and understood the ICF
  28. Patient has signed and understood the ICF
  29. Patient has signed and understood the ICF
  30. Patient has signed and understood the ICF
  31. Patient has signed and understood the ICF
  32. Patient has signed and understood the ICF
  33. Patient has signed and understood the ICF
  34. Patient has signed and understood the ICF
  35. Patient has signed and understood the ICF
  36. Patient has signed and understood the ICF
  37. Patient has signed and understood the ICF
  38. Patient has signed and understood the ICF
  39. Patient has signed and understood the ICF
  40. Patient has signed and understood the ICF
  41. Patient has signed and understood the ICF
  42. Patient has signed and understood the ICF
  43. Patient has signed and understood the ICF
  44. Patient has signed and understood the ICF
  45. Patient has signed and understood the ICF
  46. Patient has signed and understood the ICF
  47. Patient has signed and understood the ICF
  48. Patient has signed and understood the ICF
  49. Patient has signed and understood the ICF
  50. Patient has signed and understood the ICF
  51. Patient has signed and understood the ICF
  52. Patient has signed and understood the ICF
  53. Patient has signed and understood the ICF
  54. Patient has signed and understood the ICF
  55. Patient has signed and understood the ICF
  56. Patient has signed and understood the ICF
  57. Patient has signed and understood the ICF
  58. Patient has signed and understood the ICF
  59. Patient has signed and understood the ICF
  60. Patient has signed and understood the ICF
  61. Patient has signed and understood the ICF
  62. Patient has signed and understood the ICF
  63. Patient has signed and understood the ICF
  64. Patient has signed and understood the ICF
  65. Patient has signed and understood the ICF
  66. Patient has signed and understood the ICF
  67. Patient has signed and understood the ICF
  68. Patient has signed and understood the ICF
  69. Patient has signed and understood the ICF
  70. Patient has signed and understood the ICF
  71. Patient has signed and understood the ICF
  72. Patient has signed and understood the ICF
  73. Patient has signed and understood the ICF
  74. Patient has signed and understood the ICF
  75. Patient has signed and understood the ICF
  76. Patient has signed and understood the ICF
  77. Patient has signed and understood the ICF
  78. Patient has signed and understood the ICF
  79. Patient has signed and understood the ICF
  80. Patient has signed and understood the ICF
  81. Patient has signed and understood the ICF
  82. Patient has signed and understood the ICF
  83. Patient has signed and understood the ICF
  84. Patient has signed and understood the ICF
  85. Patient has signed and understood the ICF
  86. Patient has signed and understood the ICF
  87. Patient has signed and understood the ICF
  88. Patient has signed and understood the ICF
  89. Patient has signed and understood the ICF
  90. Patient has signed and understood the ICF
  91. Patient has signed and understood the ICF
  92. Patient has signed and understood the ICF
  93. Patient has signed and understood the ICF
  94. Patient has signed and understood the ICF
  95. Patient has signed and understood the ICF
  96. Patient has signed and understood the ICF
  97. Patient has signed and understood the ICF
  98. Patient has signed and understood the ICF
  99. Patient has signed and understood the ICF
  100. Patient has signed and understood the ICF
  101. Patient has signed and understood the ICF
  102. Patient has signed and understood the ICF
  103. Patient has signed and understood the ICF
  104. Patient has signed and understood the ICF
  105. Patient has signed and understood the ICF
  106. Patient has signed and understood the ICF
  107. Patient has signed and understood the ICF
  108. Patient has signed and understood the ICF
  109. Patient has signed and understood the ICF
  110. Patient has signed and understood the ICF
  111. Patient has signed and understood the ICF
  112. Patient has signed and understood the ICF
  113. Patient has signed and understood the ICF
  114. Patient has signed and understood the ICF
  115. Patient has signed and understood the ICF
  116. Patient has signed and understood the ICF
  117. Patient has signed and understood the ICF
  118. Patient has signed and understood the ICF
  119. Patient has signed and understood the ICF
  120. Patient has signed and understood the ICF
  121. Patient has signed and understood the ICF
  122. Patient has signed and understood the ICF
  123. Patient has signed and understood the ICF
  124. Patient has signed and understood the ICF
  125. Patient has signed and understood the ICF
  126. Patient has signed and understood the ICF
  127. Patient has signed and understood the ICF
  128. Patient has signed and understood the ICF
  129. Patient has signed and understood the ICF
  130. Patient has signed and understood the ICF
  131. Patient has signed and understood the ICF
  132. Patient has signed and understood the ICF
  133. Patient has signed and understood the ICF
  134. Patient has signed and understood the ICF
  135. Patient has signed and understood the ICF
  136. Patient has signed and understood the ICF
  137. Patient has signed and understood the ICF
  138. Patient has signed and understood the ICF
  139. Patient has signed and understood the ICF
  140. Patient has signed and understood the ICF
  141. Patient has signed and understood the ICF
  142. Patient has signed and understood the ICF
  143. Patient has signed and understood the ICF
  144. Patient has signed and understood the ICF
  145. Patient has signed and understood the ICF
  146. Patient has signed and understood the ICF
  147. Patient has signed and understood the ICF
  148. Patient has signed and understood the ICF
  149. Patient has signed and understood the ICF
  150. Patient has signed and understood the ICF
  151. Patient has signed and understood the ICF
  152. Patient has signed and understood the ICF
  153. Patient has signed and understood the ICF
  154. Patient has signed and understood the ICF
  155. Patient has signed and understood the ICF
  156. Patient has signed and understood the ICF
  157. Patient has